| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
10% Owner
1 company
Sands Capital Life Sciences Pulse Fund Ii, L.P. serves as a 10% Owner at IKT. Across recent SEC filings that breaks down to 1 buy and 0 sells. Those positions are worth an estimated $32.2M at current prices.
The biggest single holding is IKT (~$32.2M) as 10% Owner. Net of sales, the recent Form 4 record there shows accumulation of 2,068,965 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 21, 2025 | IKT Inhibikase Therapeutics, Inc. | 10% Owner | Buy | 2,068,965 | $1.45 | $2,999,999.25 | +18.9% | +16.8% | - |